Diiodomethane | CAS:75-11-6

We serve Diiodomethane CAS:75-11-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Diiodomethane

Chemical Name:Diiodomethane
CAS.NO:75-11-6
Synonyms:Diiodomethane
Methane, diiodo-
methylene iodide
Methylenjodid
di-iodomethane
Molecular Formula:CH2I2
Molecular Weight:267.83600
 
Physical and Chemical Properties:
Density:3.325
Melting point:6ºC
Boiling point:67-69ºC
Flash point:181ºC
Index of Refraction:1.737
 
Specification:
Appearance:Colorless to pale yellow clear liquid
Assay:≥99.0%
Moisture:≤0.3%
 
Packing:250 kg/drum, can also be packaged according to customer requirements
Storage:The substance is unstable and should be kept away from light and refrigerated
Application:Organic synthesis intermediate



Contact us for information like Diiodomethane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,di-iodomethane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Methane, diiodo- Use and application,Methane, diiodo- technical grade,usp/ep/jp grade.


Related News: As United Airlines said when suspended flights to Beijing, Shanghai and Chengdu, the decision was made “due to the continued drop in demand for travel to China and the US Department of State’s decision to raise its China travel advisory to a Level 4.”Isopropyl Chloroformate manufacturer Dr. John K. Westwick, CEO of Resonant, added “Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates.2-(Trifluoromethoxy)benzoic acid supplier But many others apparently didn’t need confirmation. Posts on Weibo, China’s Twitter-like platform, purportedly showed people lining up at night outside pharmacies across China to buy Shuanghuanglian, ironically going against the authorities’ advice to avoid congregating in public.2-Brom-xanthen-9-on vendor Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus.